Outcome of the Board Meeting held on August 13, 2025 1. Unaudited Financial Results for quarter ended June 30, 2025, along with the Limited Review Report of the Auditors thereon 2. Confirmed ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board approved unaudited standalone financial results for Q1 FY26 (quarter ended June 30, 2025). Revenue from operations fell sharply to Rs. 1,882.14 lakhs, down about 40% from Rs. 3,165.58 lakhs in the same quarter last year. Profit after tax dropped nearly 71% YoY to Rs. 256.43 lakhs (vs Rs. 880.43 lakhs), and EPS fell to Rs. 7.18 from Rs. 24.64. The Board fixed September 26, 2025 as the date for the 43rd AGM, and approved the appointment of M/s. S C Mehra & Associates LLP as the new statutory auditor for five years (FY 2025-26 to FY 2029-30), replacing M/s. M. A. Parekh & Associates whose term is ending. The Board also approved an alteration to the Object Clause of the Memorandum of Association to expand the company's permitted business into veterinary, herbal, biological, and aquaculture medicines, and cleared the Director's Report for FY25.
The steep YoY decline in both revenue and profits is a notable red flag for shareholders and may weigh on the stock in the short term, though the change is partly compared against a very strong Q1 FY25 base. On the positive side, the MoA amendment signals management's intent to diversify into animal healthcare and herbal products, which could open new growth avenues over time.